Mycotoxins are secondary metabolites produced by molds, primarily as defense mechanisms against competing microorganisms. Unlike mold spores, which are relatively large particles, many mycotoxins are small, volatile, or adsorbed onto ultrafine particles (less than 2.5 microns) that penetrate deep into the pulmonary alveoli and enter the bloodstream directly.

Once in circulation, mycotoxins behave like systemic poisons. They are lipophilic (fat-soluble), enabling them to cross cell membranes easily and accumulate in high-fat tissues including the lipid-rich membranes of cardiac cells. Key mycotoxins with documented cardiovascular effects include:

• Ochratoxin A (OTA) produced by Aspergillus ochraceus, A. carbonarius, and Penicillium verrucosum; accumulates in cardiac tissue; half-life in humans estimated at 35 days
• Trichothecenes produced by Stachybotrys chartarum (black mold) and Fusarium species; cause vascular endothelial damage and hemorrhage
• Aflatoxin B1 (AFB1) produced by Aspergillus flavus and A. parasiticus; cardiotoxic at low concentrations
• Gliotoxin produced by Aspergillus fumigatus; induces apoptosis in cardiomyocytes and suppresses immune response
• Sterigmatocystin produced by multiple Aspergillus species; damages mitochondrial function in heart cells
• Fumonisins produced by Fusarium moniliforme; disrupt sphingolipid metabolism in cardiac muscle

Ochratoxin A is among the most extensively studied mycotoxins for cardiovascular effects. It is nephrotoxic, neurotoxic, immunosuppressive, and teratogenic, but its cardiotoxicity is increasingly recognized as a major clinical concern, particularly in patients with chronic, low-level indoor mold exposure.

Mechanisms of OTA Cardiac Damage

• Oxidative stress induction: OTA generates reactive oxygen species (ROS) that overwhelm cardiomyocyte antioxidant defenses. Studies demonstrate OTA increased malondialdehyde (MDA) levels in cardiac tissue by 340% compared to controls.
• Mitochondrial dysfunction: OTA inhibits mitochondrial Complex I and Complex III in the electron transport chain, reducing ATP production. The heart, which never rests, is particularly vulnerable to this energy starvation.
• Calcium dysregulation: OTA disrupts intracellular calcium handling in cardiomyocytes, causing abnormal calcium overload that triggers arrhythmias and contractile dysfunction.
• Protein synthesis inhibition: OTA inhibits phenylalanyl-tRNA synthetase, reducing cardiac protein synthesis and impairing the heart's ability to repair and regenerate contractile proteins.
• Apoptosis induction: Multiple studies confirm OTA activates caspase-3-mediated apoptosis in cardiomyocytes at concentrations achievable in human blood after chronic indoor mold exposure.

Mycotoxin-Induced Cardiomyopathy

Cardiomyopathy is the most severe cardiac consequence of mycotoxin exposure. The condition reduces the heart's ability to pump blood effectively, leading to heart failure, arrhythmias, and sudden cardiac death if untreated. Several forms of cardiomyopathy have been linked to mycotoxin exposure:

• Dilated cardiomyopathy (DCM): The ventricles enlarge and weaken. Multiple case reports document DCM developing in patients with confirmed heavy mold exposure who lacked other DCM risk factors.
• Toxic cardiomyopathy: A pattern of diffuse myocardial damage without the classic features of ischemic disease, seen in patients with high urinary mycotoxin loads.
• Inflammatory cardiomyopathy (myocarditis): Mold-triggered immune activation leading to T-cell and macrophage infiltration of the myocardium.

Trichothecenes are a family of over 200 sesquiterpene mycotoxins produced primarily by Stachybotrys chartarum (black mold), Fusarium, Myrothecium, and related species. In water-damaged buildings, satratoxins and roridin E, both macrocyclic trichothecenes, are the primary vascular threats.

How Trichothecenes Attack Blood Vessels

• Endothelial cell death: Trichothecenes induce apoptosis and necrosis in vascular endothelial cells, the thin layer lining all blood vessels. Loss of endothelial integrity allows inflammatory cells and fluid to leak into vessel walls and surrounding tissue.
• Hemorrhagic lesions: Animal studies with satratoxin exposure consistently show hemorrhagic lesions in multiple organs, including the myocardium. This is the mechanism behind toxic hemorrhagic syndrome documented in livestock exposed to trichothecene-contaminated feed.
• Platelet dysfunction: Trichothecenes impair platelet aggregation, disrupting normal hemostasis. Paradoxically, they also promote systemic inflammation that can increase thrombotic risk, creating a dysregulated coagulation environment.
• Autonomic disruption: Trichothecenes affect CNS components controlling heart rate and blood pressure, contributing to the autonomic instability characteristic of CIRS.

Endothelial dysfunction, impaired function of the cells lining blood vessels, is increasingly recognized as the central mechanism linking mold mycotoxin exposure to cardiovascular disease. The vascular endothelium actively regulates blood vessel tone, platelet adhesion, inflammatory signaling, and coagulation. Healthy endothelium produces nitric oxide (NO), which relaxes blood vessels, prevents platelet clumping, and suppresses inflammation. Mycotoxin-exposed endothelium loses this protective function through several mechanisms:

Mold, Inflammation, and Accelerated Atherosclerosis

Beyond acute toxicity, chronic low-level mycotoxin exposure may accelerate atherosclerosis, the buildup of plaques in artery walls that underlies most heart attacks and strokes. The mechanism involves mycotoxin-induced endothelial inflammation increasing LDL oxidation and uptake into vessel walls; macrophage recruitment and foam cell formation promoted by the inflammatory cytokine environment; matrix metalloproteinases (MMPs) upregulated by trichothecenes that destabilize existing plaques; and systemic inflammation (elevated CRP, IL-6, TNF-alpha) chronically elevated in mold-exposed patients, a known independent cardiovascular risk factor.

Chronic Inflammatory Response Syndrome (CIRS), first systematically described by Dr. Ritchie Shoemaker and elaborated in peer-reviewed literature, is a multi-system illness triggered by exposure to water-damaged buildings. Cardiovascular symptoms are among the most distressing and most frequently misdiagnosed features of CIRS.

CIRS Cardiac Symptoms

• Palpitations: Awareness of irregular, rapid, or pounding heartbeats, often the first cardiac complaint in CIRS patients. Typically caused by autonomic nervous system dysregulation and electrolyte imbalances from ADH/aldosterone dysfunction.
• Tachycardia: Resting heart rates of 90 to 120 bpm are common in active CIRS. POTS-like presentations are documented, with heart rate increases of 30+ bpm on standing.
• Orthostatic hypotension: A drop in blood pressure upon standing, causing dizziness and near-syncope. Results from dysregulation of the renin-angiotensin-aldosterone system (RAAS), which CIRS disrupts through VIP depletion.
• Shortness of breath on exertion: Due to both pulmonary inflammation and reduced cardiac output from early cardiomyopathic changes.
• Chest pain and pressure: Often atypical, non-ischemic in distribution; attributed to inflammatory pericarditis or autonomic pain pathways.
• Exercise intolerance: Dramatically reduced VO2 max documented in CIRS patients, a direct measure of cardiovascular-pulmonary efficiency.

The VIP-Cardiovascular Connection

Vasoactive intestinal peptide (VIP) is a neuropeptide that regulates pulmonary vascular resistance, heart rate, and systemic blood pressure. In CIRS, VIP levels are frequently depressed, sometimes by 70 to 80% below normal. The cardiovascular consequences of VIP depletion include pulmonary artery hypertension, systemic arterial hypotension, increased airway resistance, and impaired regulation of heart rate variability (HRV). Intranasal VIP replacement is part of the Shoemaker CIRS protocol specifically because of these cardiovascular effects, and clinical improvements in exercise tolerance and blood pressure stability have been reported.

Beyond mycotoxin-mediated damage, invasive fungal infections, particularly in immunocompromised patients, can cause direct fungal myocarditis, a potentially fatal inflammation of the heart muscle caused by fungal organisms growing within cardiac tissue.

Fungal Species Causing Myocarditis

• Aspergillus fumigatus: The most common cause of invasive fungal myocarditis. Hyphae invade cardiac tissue and cause thrombosis of small coronary arteries, producing infarct-like lesions. Mortality exceeds 90% without aggressive antifungal therapy.
• Candida species: Candida myocarditis is seen in critically ill patients, post-cardiac surgery patients, and those on prolonged corticosteroids. Microabscesses in the myocardium are characteristic.
• Cryptococcus neoformans: Can cause granulomatous myocarditis in HIV patients and others with T-cell immunodeficiency.
• Histoplasma capsulatum: Endemic in the Ohio and Mississippi River valleys; pericarditis is a recognized complication of pulmonary histoplasmosis.

Diagnosing mold-related cardiovascular disease requires both cardiac biomarkers and mold/mycotoxin-specific testing. No single test is definitive; the pattern across multiple markers provides the clearest picture.

Cardiac Imaging and Functional Tests

• Echocardiography: Assesses ventricular size, function, wall motion, and diastolic dysfunction. Reduced ejection fraction in a young patient without traditional risk factors should prompt mold investigation.
• Cardiac MRI: More sensitive than echo for detecting myocardial fibrosis, edema, and inflammation. Late gadolinium enhancement patterns in toxic cardiomyopathy can support a mycotoxin etiology.
• Holter monitoring: Captures arrhythmias, particularly paroxysmal supraventricular tachycardia and premature ventricular contractions common in CIRS.
• Heart Rate Variability (HRV) testing: Reduced HRV is a sensitive early marker of cardiovascular autonomic dysfunction in mold illness patients.
• Tilt table test: Diagnoses POTS and neurocardiogenic syncope, both reported at elevated frequency in CIRS populations.

Effective treatment requires a dual approach: conventional cardiac management of the resulting cardiac condition, plus elimination of the underlying mycotoxin exposure and body burden. Treating the heart without removing the mold source produces incomplete and often temporary results.

Step 1: Remove the Mold Source

No amount of medication, supplementation, or detoxification will produce lasting improvement while the patient remains in a mold-contaminated environment. Professional mold remediation is required when mold covers more than 10 square feet or when mold is present in HVAC systems, wall cavities, or other hidden locations. The remediation process must include full containment, HEPA filtration, physical removal of all contaminated porous materials, treatment of structural surfaces with EPA-registered antimicrobial agents, and post-remediation clearance testing by an independent industrial hygienist. See our Mold Remediation Cost Guide, Mold Removal Guide, and Mold Inspection Guide for detailed process information.

Step 2: Mycotoxin Detoxification

After leaving the contaminated environment, mycotoxin detoxification focuses on binding toxins in the gastrointestinal tract and supporting hepatic metabolism. Evidence-based approaches include cholestyramine (CSM), a prescription bile acid sequestrant that binds mycotoxins in the gut with high affinity and serves as the first-line binder in the Shoemaker protocol; activated charcoal or bentonite clay for over-the-counter detox support; Welchol (colesevelam) as an alternative binder for CSM-sensitive patients; and N-acetylcysteine (NAC) and liposomal glutathione to support the liver's Phase II detoxification pathways.

Step 3: Cardiac-Specific Treatment

• For arrhythmias: Beta-blockers for rate control in tachycardia; magnesium supplementation for ectopic beats; Holter monitoring to guide specific antiarrhythmic therapy if needed.
• For cardiomyopathy: Standard heart failure therapy (ACE inhibitors or ARBs, beta-blockers, diuretics if needed); serial echocardiograms; restriction from intense exercise during active myocardial inflammation.
• For POTS/orthostatic hypotension: Increased sodium and fluid intake; compression garments; fludrocortisone or midodrine under physician supervision.
• For myocarditis: Anti-inflammatory therapy; in severe cases, immunosuppression with cardiac MRI monitoring.

Nutritional Support for Cardiac Recovery

• Coenzyme Q10 (CoQ10): Restores mitochondrial function impaired by OTA; 200 to 400 mg/day for cardiac support
• Omega-3 fatty acids: Reduce mycotoxin-amplified inflammatory signaling; cardioprotective across multiple mechanisms
• Magnesium glycinate or malate: Addresses the magnesium depletion that exacerbates arrhythmias in mold illness
• Alpha lipoic acid: Fat and water-soluble antioxidant that reduces mycotoxin-induced oxidative stress in cardiomyocytes
• Vitamin D3: Commonly deficient in mold illness; regulates cardiac remodeling and inflammatory pathways

Recovery timelines vary substantially based on the severity and duration of mold exposure, the individual's genetic susceptibility (particularly HLA-DR haplotype), the presence of established cardiomyopathy versus functional cardiovascular symptoms, and the completeness of mycotoxin detoxification.

While chronic mold exposure poses cardiovascular risks to anyone, certain groups face disproportionate danger:

• HLA-DR4 and other susceptible haplotypes: Approximately 24% of the population carries HLA haplotypes that impair biotoxin clearance. These individuals accumulate mycotoxins far more efficiently and develop CIRS symptoms at lower exposure doses.
• Pre-existing heart disease: Patients with established coronary artery disease, heart failure, or cardiomyopathy have reduced cardiac reserve and are far more vulnerable to the additional insult of mycotoxin exposure.
• Immunocompromised individuals: Those on corticosteroids, chemotherapy, or with HIV face risks of invasive fungal cardiac infection on top of mycotoxin toxicity.
• Children: Higher surface-area-to-body-mass ratio, more time spent at floor level (higher spore concentration), and developing cardiovascular systems make children especially vulnerable.
• The elderly: Reduced hepatic and renal clearance of mycotoxins, combined with age-related cardiac vulnerability, creates compounded risk.
• Pregnant women: Mycotoxins cross the placenta; fetal cardiac development may be disrupted by maternal mycotoxin exposure, particularly during the first trimester.

• Black Mold Guide
• Mold Symptoms Guide
• Mold Testing Guide
• Professional Mold Inspection Guide
• Mold Remediation Cost Guide
• Mold Removal Guide
• Basement Mold Guide
• Crawl Space Mold Guide
• Attic Mold Guide
• Mold Prevention Guide

The cardiovascular consequences of mold exposure, including mycotoxin-induced cardiomyopathy, endothelial dysfunction, CIRS-related arrhythmias, and the full spectrum of autonomic cardiovascular dysfunction, represent a serious and underrecognized public health concern. The mechanisms are real, the research base is growing, and the clinical consequences can be severe and long-lasting.

The most powerful intervention available is also the most straightforward: remove the mold. Professional remediation that physically eliminates contaminated materials, filters the air, and verifies clearance through post-remediation testing is the foundation of recovery. Medical treatment of cardiac symptoms cannot produce lasting results in a patient who continues breathing mycotoxin-laden air every day.

If you have cardiovascular symptoms and have reason to believe you have been exposed to a water-damaged building, the steps are clear: (1) Get a professional mold inspection, (2) pursue CIRS-specific laboratory testing with a knowledgeable physician, (3) arrange professional remediation of any mold discovered, and (4) pursue mycotoxin detoxification under medical supervision. Recovery is possible, but only after the source is gone.

For help with mold symptoms, testing, and remediation, see our guides on mold health symptoms, mold testing, and professional mold inspection.